EPHEDRINE-AFT SOLUTION FOR INJECTION 30MG/ML [SIN17581P]
Active ingredients: EPHEDRINE HCL EQV EPHEDRINE
Last updated on 9 October 2026
Product Info
EPHEDRINE-AFT SOLUTION FOR INJECTION 30MG/ML
[SIN17581P]
Product information
Active Ingredient and Strength | EPHEDRINE HCL EQV EPHEDRINE - 30 MG |
Dosage Form | INJECTION, SOLUTION |
Manufacturer and Country | LABORATORIOS BASI INDUSTRIA FARMACEUTICA S.A. - PORTUGAL |
Registration Number | SIN17581P |
Licence Holder | APEX PHARMA MARKETING PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | C01CA26 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 THERAPEUTIC INDICATIONS
Reversal of anaesthesia induced hypotension during spinal and epidural anaesthesia.
Dosing
4.2 DOSE AND METHOD OF ADMINISTRATION
Ephedrine-AFT injection must be diluted prior to use.
Adults and the elderly
Up to 30 mg in increments of 3 – 7.5 mg.
After the development of hypotension, by slow intravenous administration.
Paediatric Population
0.5 – 0.75 mg/kg body weight or 17 – 25 mg/m2 body surface.
After the development of hypotension, by slow intravenous administration.
Compatibilities
Ephedrine is reported to be compatible with 0.9% sodium chloride.
Contraindications
4.3 CONTRAINDICATIONS
This medicinal product must never be used in the following cases:
hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
in combination with other indirect sympathomimetic agents such as pseudoephedrine, methylphenidate, bupropion, cafedrine, and theodrenaline.
in combination with alpha sympathomimetic agents,
in combination with irreversible monoamine oxidase inhibitors (MAOI).